GHK-Cu: The Copper Peptide in Skin and Tissue Research

GHK-Cu — the copper-bound complex of the tripeptide glycyl-L-histidyl-L-lysine — is one of the most-studied small peptides in regenerative biology. Loren Pickart’s 1973 isolation of the GHK sequence from human plasma and the subsequent characterization of its copper-binding behavior launched five decades of research that has spanned fibroblast biology, collagen and matrix remodeling, gene expression, and skin and wound-bed models in animal studies. For researchers working in skin, hair, connective tissue, or matrix-remodeling contexts, GHK-Cu is one of the most thoroughly characterized research peptides available.

This overview summarizes what the peer-reviewed literature reports about GHK-Cu in research contexts: the structure of the tripeptide-copper complex, the mechanisms proposed in animal studies and cell-culture work, the gene-expression literature, the distinction between GHK Basic and the copper-bound complex, and the CoA standards a researcher should verify before committing the compound to a study. As with every research-use-only compound, GHK-Cu is sold strictly for in vitro experimentation and animal-study use, with no therapeutic, diagnostic, or human-use representation made.

What is GHK-Cu?

GHK is the tripeptide glycyl-L-histidyl-L-lysine — three amino acids, 340.38 g/mol, isolated from human plasma in 1973 by Loren Pickart at the University of California, San Francisco. The original observation was that human plasma contained a small peptide fraction that, when added to liver cultures from older animals, caused the cultures to behave more like cultures from younger animals. The active fraction was characterized as GHK.

What Pickart and subsequent investigators established is that GHK has very high affinity for divalent copper (Cu²⁺), forming a 1:1 chelate complex (GHK-Cu) with a molecular weight of approximately 401.93 g/mol. The copper ion binds at the histidine imidazole nitrogen and the deprotonated amide nitrogen between glycine and histidine, with the lysine side chain providing additional structural stabilization. The GHK-Cu complex is the form that is biologically active in most of the published research.

Standard CoA identifiers:

GHK (basic tripeptide):
CAS: 49557-75-7 (commonly cited; also see 72957-37-0 for the trihydrochloride form depending on synthesis route)
Sequence: H-Gly-His-Lys-OH
Molecular formula: C₁₄H₂₄N₆O₄
Molecular weight: 340.38 g/mol
GHK-Cu (copper complex):
CAS: 49557-75-7
Molecular formula (complex): C₁₄H₂₂CuN₆O₄
Molecular weight: ~401.93 g/mol (varies slightly by hydration state)

A research-grade vendor distinguishes between GHK (the free tripeptide) and GHK-Cu (the copper-bound complex) on the product page and on the CoA. Both should be catalogued as separate products with separate per-lot CoAs.

Mechanisms reported in the literature

The mechanistic literature on GHK-Cu organizes into three overlapping themes: copper delivery to copper-dependent enzymes, modulation of fibroblast biology and matrix remodeling, and broad gene-expression effects.

Copper delivery to copper-dependent enzymes

GHK-Cu functions, in part, as a copper transporter. The peptide presents Cu²⁺ to cell-surface copper transport proteins and to copper-dependent enzymes that require bioavailable copper for catalytic activity. These include:

Lysyl oxidase (LOX), the enzyme responsible for cross-linking collagen and elastin fibers. LOX activity is rate-limiting in extracellular matrix maturation.
Cu/Zn superoxide dismutase (SOD1), an antioxidant enzyme that requires copper as a catalytic cofactor.
Cytochrome c oxidase, the terminal complex of the mitochondrial electron transport chain.

By delivering copper to these enzymes in a bioavailable form — rather than as free Cu²⁺, which is cytotoxic at concentrations far below the GHK-Cu working range — the GHK-Cu complex supports activity of the cellular copper-utilization machinery without the toxicity of free copper ions.

Modulation of fibroblast biology and matrix remodeling

The earliest published cell-culture findings — Maquart and colleagues, working in the 1980s — reported that GHK-Cu stimulated collagen synthesis in fibroblast cultures at concentrations far below those required for general nutritive copper effects. The dose-response curve reported in their 1988 paper began at 10⁻¹² M (one picomolar) and peaked at approximately 10⁻⁹ M (one nanomolar), with activity attributable specifically to the GHK-Cu complex rather than to copper alone or GHK alone [Maquart F-X et al., 1988, PMID 3169264].

Subsequent work has expanded the matrix-remodeling picture. Cell-culture studies have reported that GHK-Cu modulates both the synthesis and the breakdown of collagen and glycosaminoglycans — not simply by increasing collagen, but by modulating matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). The reported result is a net remodeling effect rather than a purely additive one. The 2015 BioMed Research International review by Pickart and Margolina synthesized this body of work and proposed that GHK-Cu functions as a multi-pathway modulator of cellular regeneration [Pickart L, Margolina A, 2015, DOI 10.1155/2015/648108, PMC4508379].

Animal studies have reported that topical or intradermal GHK-Cu administration in animal models is associated with measurable changes in skin collagen content, increased dermal cellularity, and modulation of wound-bed extracellular matrix composition. Findings have been reported in models of burn wound healing, full-thickness excisional wounds, and aged-skin remodeling. These animal-study findings are research observations and do not establish efficacy in humans.

Gene-expression effects

A 2010 transcriptomics study by Hong et al. — frequently cited in the GHK-Cu literature — used the Broad Institute’s Connectivity Map database to characterize the gene-expression signature of GHK exposure in cultured human cells. The reported signature included modulation of more than 4,000 genes, with up- and downregulation of pathways involved in DNA repair, antioxidant defense, fibroblast function, and tissue remodeling [Hong Y et al., 2010; reviewed in Pickart 2015].

The 4,000-gene number is widely cited and should be read in context: it reflects modulation across multiple cell types and conditions, with effect sizes ranging from large to subtle. The mechanistic specificity that translates from a broad transcriptomic signature into measurable cellular outcomes is the subject of ongoing work.

A 2017 paper by Pickart and colleagues reported that GHK at picomolar concentrations modulated TGF-β signaling and PI3K/Akt pathway activity in fibroblast models, providing one of the candidate signaling axes that would translate the broad gene-expression signal into measurable downstream effects on fibroblast proliferation and matrix synthesis.

Categories of animal-study findings

The published animal-study literature on GHK-Cu organizes into several research contexts. As with all preclinical data, these findings are research observations and do not establish safety or efficacy in any species, including humans.

Skin and dermal models

The largest category. Animal studies have reported that GHK-Cu, applied topically or by intradermal injection in animal models, was associated with changes in dermal collagen content, increased fibroblast cellularity, and modulation of dermal-junction architecture. Studies have used both young-animal models (wound-healing rates) and aged-animal models (matrix remodeling in intrinsically aged skin).

Wound-bed and burn models

Animal studies of full-thickness excisional wounds and of partial-thickness burn injuries have reported findings consistent with altered wound-bed remodeling, including changes in the timing of granulation tissue formation and modulation of collagen organization in the healing wound. The proposed mechanistic pathway invokes both LOX-mediated cross-linking effects and direct modulation of fibroblast activity.

Hair-follicle models

A smaller body of work has reported effects of GHK-Cu in animal models of hair-follicle biology, with findings consistent with modulation of dermal-papilla activity and follicle-cycle dynamics. This research context is the source of some of the consumer interest in GHK-Cu as a topical compound; the animal-study literature is the basis, and it does not extrapolate to human cosmetic claims.

Stem-cell and progenitor-cell findings

Cell-culture studies have reported GHK-Cu effects on bone-marrow-derived stem cells and on dermal progenitor populations, with findings consistent with modulation of proliferation and differentiation. The 2015 Pickart review collects the citations in this category.

GHK Basic vs. GHK-Cu

A common point of confusion: the free tripeptide GHK and the copper-bound complex GHK-Cu are not interchangeable in research.

GHK (free): the unbound tripeptide. Useful for studies that need the peptide structure but not the copper chelation — for example, studies investigating GHK binding to plasma proteins or studies that need to add copper separately at a controlled concentration.
GHK-Cu (copper complex): the biologically active form in the majority of the published literature. Required for studies that intend to replicate the established collagen-synthesis, gene-expression, and wound-healing findings.

A research-grade vendor publishes both. The mass-spectrometry CoA distinguishes them by molecular weight: ~340 for GHK; ~402 for GHK-Cu. Each should be catalogued as a separate product with its own per-lot CoA.

What researchers should look for in a GHK-Cu CoA

Beyond the standard CoA fields covered in How to Read a Peptide Certificate of Analysis, GHK-Cu has specific verification points:

The molecular weight on the mass spectrum should match the copper complex (~401.93 Da), not the free tripeptide (~340.38). A CoA reporting ~340 for a vial labeled “GHK-Cu” is a CoA for GHK Basic, not GHK-Cu — either a labeling error or a different product.
The CoA should specify the copper-loading ratio. Ideally 1:1 Cu:peptide (the stoichiometric complex). A reported ratio below 1:1 indicates incomplete copper loading; the vial contains a mixture of GHK and GHK-Cu rather than the pure complex.
Visual confirmation: GHK-Cu is blue. The copper complex carries a characteristic deep blue color in solid form and in solution at research-working concentrations. A “GHK-Cu” vial whose contents appear white or off-white may be GHK without copper loading. (The intensity of color varies with concentration and lighting, so use this as a directional check, not a quantitative test.)
HPLC purity ≥ 99.0% by area, with the chromatogram showing a sharp main peak. Standard.
Lot number matching the vial.

Researchers should verify whether the vendor sells GHK-Cu pre-complexed in solid form or requires adding copper in solution at reconstitution time. The pre-complexed form (lyophilized GHK-Cu, ready for direct reconstitution) is generally preferable for reproducibility.

Storage and handling in a research setting

GHK-Cu, like other lyophilized research peptides, is stable for extended periods when properly stored:

Before reconstitution: 2–8°C, dry, away from light. The copper complex is light-sensitive over long timeframes — refrigerated storage in the original packaging (or amber-glass / wrapped vial) is the conservative default for ongoing stability. For multi-year archival storage, -20°C in a low-humidity environment extends shelf life further.
After reconstitution: 2–8°C, use within 28 days, with bacteriostatic water as the standard reconstitution medium for multi-dose research vials.

GHK-Cu in reconstituted solution should retain its characteristic blue color; loss of color suggests either copper dissociation (the complex has dissociated to free GHK and Cu²⁺) or oxidation. Solutions that have visibly changed color should be discarded.

For more on reconstitution protocols and storage tradeoffs, see the storage protocol guide.

Limitations of the GHK-Cu literature

A fair summary acknowledges the gaps:

Cell-culture findings vs. in vivo translation. Much of the most-cited mechanistic literature is cell-culture work. Animal-study findings have been reported and are referenced above, but the translation from animal models to human clinical contexts is not the subject of this article and is not established.
Concentration-dependence and dosing context. The strongest cell-culture findings are at picomolar to low-nanomolar GHK-Cu concentrations. Translating these to topical or systemic administration in animal models requires careful pharmacokinetic consideration that varies across studies.
Multiple proposed mechanisms. The broad gene-expression signal, the LOX-mediated matrix-remodeling effect, the TGF-β/PI3K-Akt signaling effect, and the copper-transport effect are not mutually exclusive but also have not been integrated into a single mechanistic model. The literature reports multiple effects; the question of which dominates in a given research context is unresolved.
Cosmetic-industry overlap. Some of the most-cited literature on GHK-Cu sits at the intersection of pharmaceutical research and cosmetic ingredient development. The methodological standards across that border vary. Researchers should weight peer-reviewed primary literature over industry-sponsored review pieces when assessing claims.

How GHK-Cu sits in the broader research catalog

GHK-Cu is often catalogued alongside other tissue-repair research compounds — GHK Basic, and blend preparations combining GHK-Cu with BPC-157, TB-500, or KPV. These blends are used in research designs that target multiple pathways simultaneously.

For researchers planning a matrix-remodeling or fibroblast-biology study, GHK-Cu is also frequently used in combination with BPC-157 (see BPC-157: A Complete Research Overview) and TB-500 in published animal-study designs.

Summary

GHK-Cu is the copper-bound complex of the tripeptide glycyl-L-histidyl-L-lysine, isolated from human plasma in 1973 and characterized across five decades of fibroblast biology, matrix-remodeling, and gene-expression research. The mechanistic literature describes copper delivery to copper-dependent enzymes (LOX, SOD1, cytochrome c oxidase), modulation of fibroblast collagen synthesis at picomolar-to-nanomolar concentrations, and broad gene-expression effects affecting thousands of human genes. Animal-study findings have been reported in skin, wound-bed, hair-follicle, and stem-cell research contexts. The free tripeptide (GHK) and the copper complex (GHK-Cu) are distinct research compounds and should not be substituted.

Researchers ordering GHK-Cu should verify the mass spectrum confirms the copper complex (~402 Da), the copper-loading ratio is 1:1, HPLC purity is ≥ 99.0%, and the lot number on the CoA matches the vial. Standard lyophilized-peptide storage applies, with attention to light exposure for long-term storage of the copper complex.

Selected peer-reviewed sources

Maquart F-X, et al. “Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺.” PMID 3169264. https://pubmed.ncbi.nlm.nih.gov/3169264/
Pickart L, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” BioMed Research International (2015). DOI 10.1155/2015/648108. PMC4508379. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508379/
Pickart L. “Resetting Skin Genome Back to Health Naturally with GHK.” Springer reference. https://link.springer.com/rwe/10.1007/978-3-642-27814-3_162-1
Sarbaziha N, et al. “Copper Peptides in Regenerative Aesthetic Dermatology.” Dermatological Reviews (2026). https://onlinelibrary.wiley.com/doi/abs/10.1002/der2.70067
Pickart L, Vasquez-Soltero JM, Margolina A. “GHK peptide as a copper-binding modulator of multiple cellular pathways.” Background reference for the GHK-Cu mechanism literature; the 2015 review is the primary citation.

Research Use Only — Disclaimer

GHK, GHK-Cu, and related research peptides discussed on this page are described for laboratory and research purposes only. They are intended exclusively for in vitro experimentation and for use in animal studies under appropriate institutional oversight. They are not drugs, dietary supplements, cosmetics, or food additives. They are not for human consumption, not for topical use, not for veterinary use in companion animals, and not for any therapeutic, diagnostic, preventive, or palliative purpose.They are not drugs, dietary supplements, cosmetics, or food additives. They are not for human consumption, not for topical use, not for veterinary use in companion animals, and not for any therapeutic, diagnostic, preventive, or palliative purpose.

Nothing on this page constitutes medical or cosmetic advice. No statement on this page should be interpreted as a recommendation, claim, or representation that any peptide compound is safe, effective, or appropriate for any use in humans. Animal-study findings reported in the peer-reviewed literature are described for research context only and do not establish safety or efficacy in any species, including humans.

Buyers must be at least 21 years of age and must agree to use products strictly for research purposes.